Treatment resistant hypertension

Ethnicity and Disease

Volumn 25, Issue 4, 2015, Pages 495-498

  Egan, Brent M ^a  

^a Care Coordination Institute   (United States)

Author keywords

Apparent Treatment Resistant Hypertension; Hypertension

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; RENIN;

ARTIFACT; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CONFERENCE PAPER; DIURETIC THERAPY; DRUG EFFICACY; ETHNICITY; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HUMAN; HYPERTENSION; MEDICATION COMPLIANCE; PATIENT REFERRAL; PRESCRIPTION; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIMARY MEDICAL CARE; TREATMENT RESISTANT HYPERTENSION; TREATMENT RESPONSE; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; DIURETICS; HUMANS; HYPERTENSION; PREVALENCE; RENIN; UNITED STATES;

EID: 84962734446     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: 10.18865/ed.25.4.495     Document Type: Conference Paper

References (15)

1. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9):1046-1058. http://dx.doi.org/10.1161/CIRCULATIONAHA.111.030189. PMID:21824920.
2. Calhoun DA, Jones D, Textor S, et al; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51(6):1403-1419. http://dx.doi.org/10.1161/HYPERTENSIONAHA.108.189141. PMID:18391085.
3. Egan BM, Zhao Y, Li J, et al. Prevalence of optimal treatment regimens in patients with apparent treatment resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013;62:691-697. http://dx.doi.org/10.1161/HYPERTENSIONAHA.113.01448. PMID:23918752.
4. Myers MG, Kaczorowski J, Dawes M, Godwin M. Automated office blood pressure measurement in primary care. Can Fam Physician. 2014;60(2):127-132. PMID:24522674.
5. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46(1):156-161. http://dx.doi.org/10.1161/01.HYP.0000170138.56903.7a. PMID:15939805.
6. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension. 2006;47(5):846-853. http://dx.doi.org/10.1161/01.HYP.0000215363.69793.bb. PMID:16567588.
7. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028-3035. http://dx.doi.org/10.1161/CIRCULATIONAHA.108.768986. PMID:19528344.
8. Bosworth HB, Powers BJ, Olsen MK, et al. Home blood pressure management and improved blood pressure control: results from a randomized controlled trial. Arch Intern Med. 2011;171(13):1173-1180. http://dx.doi.org/10.1001/archinternmed.2011.276. PMID:21747013.
9. Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54(3):475-481. http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.131235. PMID:19620517.
10. Appel LJ, Moore TJ, Obarzanek E, et al; DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997;336(16):1117-1124. http://dx.doi.org/10.1056/NEJM199704173361601. PMID:9099655.
11. Friedman O, Bradley TD, Chan CT, Parkes R, Logan AG. Relationship between overnight rostral fluid shift and obstructive sleep apnea in drug-resistant hypertension. Hypertension. 2010;56(6):1077-1082. http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.154427. PMID:21060007.
12. Gaddam K, Pimenta E, Thomas SJ, et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010;24(8):532-537. http://dx.doi.org/10.1038/jhh.2009.96. PMID:20016520.
13. Mattsson C, Young WF Jr. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol. 2006;2(4):198-208. http://dx.doi.org/10.1038/ncpneph0151. PMID:16932426.
14. Kaplan NM, Calhoun DA. Treatment resistant hypertension. UpToDate (http://www.uptodate.com/contents/treatment-of-resistant-hypertension [accessed 24 Aug 2015]).
15. Egan BM, Basile JN, Rehman SU, et al. Plasma renin test-guided drug treatment for correcting patients with treated but uncontrolled hypertension: a randomized-controlled clinical trial. Am J Hypertens. 2009;22(7):792-801. http://dx.doi.org/10.1038/ajh.2009.63. PMID:19373213.